The company accelerated clients' R&D and ensured agility by leveraging a global footprint, keen customer focus, and customized solutions.
LONDON, Dec. 2, 2020 /PRNewswire/ -- Based on its recent analysis of the global contract research organization (CRO) market, Frost & Sullivan recognizes WuXi AppTec with the 2020 Global Customer Value Leadership Award. WuXi AppTec offers end-to-end services in R&D and manufacturing that enable companies in the pharmaceutical, biotech, and medical device industries to advance discoveries and deliver innovative treatments. It has been expanding its industry-leading services rapidly, with a particular focus on contract development and manufacturing for small molecules, peptides, oligonucleotides, and cell and gene therapies (CGT).
Even as COVID-19 continues to pose a risk to ongoing clinical trials and new trials' initiation, WuXi AppTec has ensured business continuity for its partners by adopting virtual trial protocols and shifting workloads between sites. Its efforts also include building new scientific capabilities, such as developing a set of in vitro biology assays against various novel drug targets of COVID-19 at record speed. This has helped the company expeditiously deliver preclinical testing packages for potential COVID-19 treatments. Furthermore, the company worked with regulatory officials, healthcare professionals, and advisors to plan and execute new guidelines on remote monitoring and virtual trials through its subsidiary, WuXi Clinical.
"WuXi AppTec's differentiated customer service approach emphasizes understanding the different needs of its customers and accordingly curating customized packages," said Deepak Jayakumar, Industry Analyst. "Instead of presenting clients with an unnecessary comprehensive package, it offers client-specific and feature-integrated services or bundles. The customized packages enable rapid testing and turnaround of experiments and scientific hypotheses through access to the company's advanced technologies. The company has also custom-built systems and processes within several business functions to improve real-time project tracking."
Meanwhile, WuXi AppTec's range of service offerings to support the development of CGT includes process development and manufacturing services, integrated testing and analytical development services, and manufacturing support. With process development, manufacturing, and testing facilities on two continents, with the capacity and capability to support customers globally, WuXi AppTec can help customers access all major markets.
"WuXi AppTec has strived to identify populations with the greatest clinical trial potential while advancing trials that incorporate local best practices and expertise," noted Jayakumar. "Robust demand, an increase in capacity utilization, and efficient operations, along with its focus on providing best-in-class services, have helped WuXi AppTec garner significant business opportunities across different stages of the drug development process."
Each year, Frost & Sullivan presents this award to the company that has demonstrated excellence in implementing strategies that proactively create value for its customers with a focus on improving the return on the investment that customers make in its services or products. The award recognizes the company's unique focus on augmenting the value that its customers receive, beyond simply good customer service, leading to improved customer retention and customer base expansion.
Frost & Sullivan Best Practices awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.
About Frost & Sullivan
For six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.
About WuXi AppTec
WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. As an innovation-driven and customer-focused company, WuXi AppTec helps our partners improve the productivity of advancing healthcare products through cost-effective and efficient, socially responsible and sustainable solutions – and has received ESG (Environment, Social and Governance) A Ratings from Morgan Stanley Capital International's since 2019. With industry-leading capabilities such as R&D and manufacturing for small molecule drugs, cell and gene therapies, and testing for medical devices, WuXi AppTec's open-access platform is enabling more than 4,100 collaborators from over 30 countries to improve the health of those in need – and to realize our vision that "every drug can be made and every disease can be treated." Please visit: www.wuxiapptec.com
SOURCE Frost & Sullivan